Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin Bremer

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 2, 2024
Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinasesLu Wang, Yusheng Lin, Zhimeng Yao, et al.
Pharmaceutics|May 4, 2026
A Novel Hypothermic Preservation Formulation Containing SUL-138 Enables Long-Term Hypothermic Storage of Clinical-Grade CAR-T CellsAysenur Öner, Nina Nooteboom, Linette Oosting, et al.
Gastroenterology|July 3, 2023
Salivary Extracellular MicroRNAs for Early Detection and Prognostication of Esophageal Cancer: A Clinical StudyKai Li, Yusheng Lin, Yu Zhou, et al.
Cancers|April 23, 2022
Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial CancerJoyce M Lubbers, Marta A Ważyńska, Nienke van Rooij, et al.
Biorxiv : the Preprint Server for Biology|February 27, 2026
A universal platform for simultaneous TCRα/β removal enables safer and more potent TCR therapies and autoimmune modelingGiorgia Zanetti, Mateusz Legut, Austin Chen, et al.
Journal of Molecular Medicine (Berlin, Germany)|February 21, 2024
Novel high-yield potato protease inhibitor panels block a wide array of proteases involved in viral infection and crucial tissue damageNienke Visser, Laure C M Herreman, Jennifer Vandooren, et al.
Molecular Cancer Therapeutics|January 24, 2026
DSP502 combines dual inhibition of PD-L1 and PVR to trigger anti-cancer immune responsesVinicio A Melo Gallegos, Shirley Greenwald, Ami Tamir, et al.
Journal of Translational Medicine|January 16, 2026
Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemiaJimena Álvarez Freile, Lena Rockstein, Rianne Kloosterman, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 15, 2022
DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunityEwa Cendrowicz, Lisa Jacob, Shirley Greenwald, et al.
Oncotarget|September 22, 2016
CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapyFenne L Komdeur, Maartje C A Wouters, Hagma H Workel, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 2, 2024
Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinasesLu Wang, Yusheng Lin, Zhimeng Yao, et al.
Pharmaceutics|May 4, 2026
A Novel Hypothermic Preservation Formulation Containing SUL-138 Enables Long-Term Hypothermic Storage of Clinical-Grade CAR-T CellsAysenur Öner, Nina Nooteboom, Linette Oosting, et al.
Gastroenterology|July 3, 2023
Salivary Extracellular MicroRNAs for Early Detection and Prognostication of Esophageal Cancer: A Clinical StudyKai Li, Yusheng Lin, Yu Zhou, et al.
Cancers|April 23, 2022
Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial CancerJoyce M Lubbers, Marta A Ważyńska, Nienke van Rooij, et al.
Biorxiv : the Preprint Server for Biology|February 27, 2026
A universal platform for simultaneous TCRα/β removal enables safer and more potent TCR therapies and autoimmune modelingGiorgia Zanetti, Mateusz Legut, Austin Chen, et al.
Journal of Molecular Medicine (Berlin, Germany)|February 21, 2024
Novel high-yield potato protease inhibitor panels block a wide array of proteases involved in viral infection and crucial tissue damageNienke Visser, Laure C M Herreman, Jennifer Vandooren, et al.
Molecular Cancer Therapeutics|January 24, 2026
DSP502 combines dual inhibition of PD-L1 and PVR to trigger anti-cancer immune responsesVinicio A Melo Gallegos, Shirley Greenwald, Ami Tamir, et al.
Journal of Translational Medicine|January 16, 2026
Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemiaJimena Álvarez Freile, Lena Rockstein, Rianne Kloosterman, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 15, 2022
DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunityEwa Cendrowicz, Lisa Jacob, Shirley Greenwald, et al.
Oncotarget|September 22, 2016
CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapyFenne L Komdeur, Maartje C A Wouters, Hagma H Workel, et al.
Pageof 10